STATEMENT: The International Society for Cellular and Gene Therapies (ISCT) and the International Society for Extracellular Vesicles (ISEV) recognize the potential of extracellular vesicles (EVs, including exosomes) from mesenchymal stromal cells (MSCs) and possibly other cell sources as treatments for COVID-19. Research and trials in this area are encouraged. However, ISEV and ISCT do not currently endorse the use of EVs or exosomes for any purpose in COVID-19, including but not limited to reducing cytokine storm, exerting regenerative effects or delivering drugs, pending the generation of appropriate manufacturing and quality control provisions, pre-clinical safety and efficacy data, rational clinical trial design and proper regulatory oversight.

International Society for Extracellular Vesicles and International Society for Cell and Gene Therapy statement on extracellular vesicles from mesenchymal stromal cells and other cells: considerations for potential therapeutic agents to suppress coronavirus disease-19

Bussolati B.;
2020-01-01

Abstract

STATEMENT: The International Society for Cellular and Gene Therapies (ISCT) and the International Society for Extracellular Vesicles (ISEV) recognize the potential of extracellular vesicles (EVs, including exosomes) from mesenchymal stromal cells (MSCs) and possibly other cell sources as treatments for COVID-19. Research and trials in this area are encouraged. However, ISEV and ISCT do not currently endorse the use of EVs or exosomes for any purpose in COVID-19, including but not limited to reducing cytokine storm, exerting regenerative effects or delivering drugs, pending the generation of appropriate manufacturing and quality control provisions, pre-clinical safety and efficacy data, rational clinical trial design and proper regulatory oversight.
2020
22
9
482
485
Coronavirus Infections; Exosomes; Humans; Mesenchymal Stem Cells; Societies, Scientific; Extracellular Vesicles
Borger V.; Weiss D.J.; Anderson J.D.; Borras F.E.; Bussolati B.; Carter D.R.F.; Dominici M.; Falcon-Perez J.M.; Gimona M.; Hill A.F.; Hoffman A.M.; de Kleijn D.; Levine B.L.; Lim R.; Lotvall J.; Mitsialis S.A.; Monguio-Tortajada M.; Muraca M.; Nieuwland R.; Nowocin A.; O'Driscoll L.; Ortiz L.A.; Phinney D.G.; Reischl I.; Rohde E.; Sanzenbacher R.; Thery C.; Toh W.S.; Witwer K.W.; Lim S.K.; Giebel B.
File in questo prodotto:
File Dimensione Formato  
Börger et al. COVID-19 2020 .pdf

Accesso aperto

Tipo di file: PREPRINT (PRIMA BOZZA)
Dimensione 140.33 kB
Formato Adobe PDF
140.33 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1758797
Citazioni
  • ???jsp.display-item.citation.pmc??? 57
  • Scopus 86
  • ???jsp.display-item.citation.isi??? 82
social impact